IBOG.F Stock Overview
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Universal Ibogaine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.011 |
| 52 Week High | CA$0.062 |
| 52 Week Low | CA$0.0038 |
| Beta | 4.74 |
| 1 Month Change | -23.45% |
| 3 Month Change | 50.00% |
| 1 Year Change | 11.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBOG.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -19.0% | 3.0% | 1.6% |
| 1Y | 11.0% | 4.0% | 26.2% |
Return vs Industry: IBOG.F exceeded the US Healthcare industry which returned 3.5% over the past year.
Return vs Market: IBOG.F underperformed the US Market which returned 26% over the past year.
Price Volatility
| IBOG.F volatility | |
|---|---|
| IBOG.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBOG.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine IBOG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Karos | universalibogaine.com |
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.
Universal Ibogaine Inc. Fundamentals Summary
| IBOG.F fundamental statistics | |
|---|---|
| Market cap | US$3.20m |
| Earnings (TTM) | -US$867.69k |
| Revenue (TTM) | US$1.63m |
2.0x
P/S Ratio-3.7x
P/E RatioIs IBOG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBOG.F income statement (TTM) | |
|---|---|
| Revenue | CA$2.22m |
| Cost of Revenue | CA$1.58m |
| Gross Profit | CA$640.33k |
| Other Expenses | CA$1.83m |
| Earnings | -CA$1.19m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 28.79% |
| Net Profit Margin | -53.30% |
| Debt/Equity Ratio | 153.6% |
How did IBOG.F perform over the long term?
See historical performance and comparison